<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326662</url>
  </required_header>
  <id_info>
    <org_study_id>FMBA OPH1</org_study_id>
    <nct_id>NCT02326662</nct_id>
  </id_info>
  <brief_title>Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury</brief_title>
  <official_title>Safety and Efficacy of Autologous Neural Stem Cell Transplantation in Patients With Traumatic Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novagenesis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ophiuchus Technologies AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal Research Clinical Center of Federal Medical &amp; Biological Agency, Russia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research investigates the use of autologous neural stem cells in patients with complete
      traumatic spinal cord injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate Mesenchymal Stem Cells [MSC]-derived autologous neural
      stem cells transplantation as a safe and potentially beneficial treatment for patients with
      traumatic spinal cord injury.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and safety of autologous Neural Stem Cell transplantation in patients with complete traumatic spinal cord injury as measured by reported side effects and surgery procedure</measure>
    <time_frame>24 months</time_frame>
    <description>Side effects is recorded by the hospital staff, in the CRF and by the patient. Surgery procedure is documented by video and standard recording</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>324-point ASIA and other scoring incl. muscle control and voluntary movement and improvement of sphincters control</measure>
    <time_frame>3, 6,12, 24 months and 3 year follow-up</time_frame>
    <description>Change from Baseline in ASIA Score. All patients are stable ASIA A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Scan of Spinal Cord</measure>
    <time_frame>3, 6,12, 24 months and 3 year follow-up</time_frame>
    <description>Change from Baseline of Injury Area. All patients has spinal cord injuries visible on MRI</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Paraplegics Acute</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute [1-6 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paraplegics Sub-chronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sub-chronic [6-12 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paraplegics Chronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic [1- 5 years]) patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.
Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetraplegics Acute</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute [1-6 mo.] patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetraplegics Sub-chronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sub-chronic [6-12 mo.] patients (tetraplegics) with complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.
Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tetraplegics Chronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic [1- 5 years]) patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells Intervention: Autologous Stem Cell Transplantation &amp; Biomatrix</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cell Transplantation</intervention_name>
    <description>Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed</description>
    <arm_group_label>Paraplegics Acute</arm_group_label>
    <arm_group_label>Paraplegics Sub-chronic</arm_group_label>
    <arm_group_label>Paraplegics Chronic</arm_group_label>
    <arm_group_label>Tetraplegics Acute</arm_group_label>
    <arm_group_label>Tetraplegics Sub-chronic</arm_group_label>
    <arm_group_label>Tetraplegics Chronic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 50 years old

          -  Traumatic spinal cord injury at the neck, thoracic or lumbar level

          -  Classification ASIA A and B with no significant further improvement with physical
             therapy/rehabilitation

          -  A score of less than 200 in the 324-point ASIA scale

          -  Injury duration 1 month to 5 years

        Exclusion Criteria:

          -  An advanced, severe, or unstable disease of any type that may interfere with primary
             and secondary variable evaluations, including any medical condition that could be
             expected to progress, recur, or change to such an extent that it may bias the
             assessment of the clinical or mental status of the patient to a significant degree or
             put the patient at special risk (e.g., severe liver or kidney disease,
             malignancies/cancer)

          -  Immune system disorder or dysfunction

          -  Any major/serious infections up to 2 months prior to inclusion

          -  A disability that may prevent the patient from completing all study requirements
             (e.g., blindness, deafness, severe language difficulty)

          -  A current diagnosis of active, uncontrolled peptic ulceration within the last three
             months

          -  A current diagnosis of acute, severe, or unstable asthmatic conditions [e.g., severe
             chronic obstructive pulmonary disease (COPD)]

          -  Participated in any other investigational trial within 4 weeks of initial screening
             and within 7 weeks of study entry

          -  History of regular alcohol intake or drug abuse in the previous 3 months and not able
             to sustain from alcohol intake during the trial Cardiovascular

          -  A current diagnosis of severe or unstable cardiovascular disease

          -  A current diagnosis of sick-sinus syndrome or conduction deficits (e.g., sino-atrial
             block, second or third degree atrio-ventricular block)

          -  A current diagnosis of uncontrolled atrial fibrillation (&gt;100 bpm)

          -  A current diagnosis of moderate to severe heart failure [New York Heart Association
             (NYHA), Class III or more]

          -  A myocardial infarction (MI) known to have occurred within the last 3 months

          -  A current diagnosis of severe or unstable angina

          -  Vital signs (supine) outside the following ranges

          -  Systolic blood pressure below 90 or above 160 mmHg

          -  Diastolic blood pressure below 55 or above 95 mmHg

          -  Radial pulse below 50 or above 100 bpm CNS related

          -  A recent history of up to one year or currently diagnosed with cerebrovascular disease
             (e.g., stroke transient ischemic attacks, aneurysms)

          -  A current diagnosis of any primary neuro-degenerative disorder [e.g., Huntington's
             disease, Parkinson's disease etc.]

          -  A current diagnosis of an active, uncontrolled seizure disorder Psychiatric

          -  A current DSM-IV diagnosis of major depression

          -  Any other DSM-IV Axis 1 diagnosis that may interfere with the response of the patient
             to study medication, including other primary degenerative dementia, schizophrenia, or
             bipolar disorder Laboratory abnormalities

          -  Clinically significant abnormalities in routine laboratory examinations (hematology,
             electrolytes, biochemistry, liver and kidney function tests, urinanalysis) Concomitant
             therapy

          -  Previous stem cell treatment

          -  Ingested any of the following substances

          -  An investigational drug during the past 6 months

          -  A drug or treatment known to cause effect on the central nervous system [CNS] during
             the past four weeks

          -  A drug or treatment known to cause major organ system toxicity during the past four
             weeks

          -  Anticholinergic drugs at baseline

          -  Medication for Parkinson's disease at baseline (e.g., selegiline, levodopa,
             amantadine, dopamine agonists, COMT inhibitors)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Averyanov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal Research Clinical Center FMBA of Russia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal Research Clinical Center FMBA of Russia</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2014</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>neural stem cells</keyword>
  <keyword>paraplegia</keyword>
  <keyword>transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

